Page results
-
Men currently attending a hospital outpatient clinic for prostate hormone injections every 3 or 6 months will be advised that (unless not clinically appropriate) their next injection will be administered at a local GP practice, usually by the practice nurse.
-
All semen analysis referrals should be made via the NHS e-Referral Service (e-RS). We will no longer be able to book semen analysis appointments through direct requests from patients or GP surgeries via email.
-
UCLH is delighted that His Majesty King Charles III has accepted the patronages of University College Hospital and the Royal London Hospital for Integrated Medicine.
-
We are now administering new COVID-19 treatments for patients at highest risk in the community. The service can prescribe oral antivirals to be taken at home, and give intravenous antibody treatments at the hospital.
-
Thank you for helping the Hospital for Tropical Diseases celebrate 100 years in 2022
-
Professor Beate Diehl is a consultant neurologist, clinical neurophysiologist and clinical senior lecturer.
-
The UCLH trauma and orthopaedics team has reached a milestone of 1000 operations on hips and knees using the Mako robot.
-
Freedom of Information request
-
Dr Rather is a consultant physician & geriatrician with special interests in supporting patients with Parkinson’s, stroke and dementia. He also specialises in peri-operative care.
-
Volunteers are being asked to sign up to the latest Covid-19 vaccine study to begin across the UK including at UCLH.
File results
-
FOI/2023/0550 - Varicose veins referrals, treatment and wait time
-
FOI/2023/0553 - Maternity complaints by ethnicity
-
FOI/2023/0559 - Patients admitted to hospital with dental distress
-
FOI/2023/0560 - Digital maternity training platform
-
FOI/2023/0561 - Birthrate Plus
-
FOI/2023/0563 - Treatment for Haemophilia B and Von Willebrand disease
-
FOI/2023/0565 - Rare diseases - diagnosis/ treatment for Fabry/ Gaucher/ Pompe
-
FOI/2023/0566 - Structure chart for IM &T, Business Intelligence, Informatics
-
FOI/2023/0569 - Treatment for Ruxolitinib
-
FOI/2023/0578 - Spinal Muscular Atrophy (SMA) patients